Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Harvard Business School

Generated: September 23, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,415,332

  Try a free trial

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,415,332
Title:Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
Abstract: The present invention provides ascending-dose extended cycle regimens in which a female is administered an estrogen and a progestin for a period of greater than 30 or 31 consecutive days, optionally followed by a hormone-free period or by a period of administration of estrogen. The disclosed regimens can be administered to a female to provide contraceptive and non-contraceptive benefits.
Inventor(s): Diliberti; Charles E. (Montclair, NJ), Reape; Kathleen Z. (Bryn Mawr, PA), Bronnenkant; Lance J. (Snyder, NY)
Assignee: Teva Woman's Health, Inc. (Woodcliff Lake, NJ)
Application Number:11/892,026
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,415,332
Patent Claim Types:
see list of patent claims

Drugs Protected by US Patent 8,415,332

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Teva Branded Pharm QUARTETTE ethinyl estradiol; levonorgestrel TABLET;ORAL 204061-001 Mar 28, 2013 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,415,332

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 051931 ➤ Sign Up
Australia 2005294269 ➤ Sign Up
Brazil PI0516247 ➤ Sign Up
Brazil PI0716291 ➤ Sign Up
Canada 2582530 ➤ Sign Up
Canada 2668211 ➤ Sign Up
China 101068552 ➤ Sign Up
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.